News

European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including multiple sclerosis, so to better predict a patient’s likely response to treatment and likely disease progression. The project, called 3TR…

Vumerity Approved in US as Treatment for RRMS and Active SPMS

The U.S. Food and Drug Administration (FDA) has approved Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive disease (SPMS). Vumerity (previously known as ALKS 8700) was developed by Alkermes…

Unemployment Risk Factors in MS Vary with Age, Study Suggests

Physical symptoms and poorer coping mechanisms are major risk factors for unemployment in younger and older people with multiple sclerosis (MS), while psychological problems have the greatest impact in middle-aged patients’ unemployment, a study suggests. These findings highlight that unemployment risk factors vary with age and call for interventions…

Higher Intellectual Ability, Early-life Physical Activity May Protect Against Cognitive Impairment in MS, Study Suggests

Higher intellectual ability and physical activity during childhood and adolescence may help protect against the development of cognitive impairment in people with multiple sclerosis (MS), an Italian study suggests. These findings, though preliminary, suggest that intellectual enrichment and early-life physical activity may reduce the likelihood of developing cognitive deficits…

SARM1 Inhibitors Protect Neurons from Damage in Mice and Cell Cultures, Results Presented at Neuroscience 2019 Show

SARM1 inhibitors are a potential oral treatment to slow disease progression in neurodegenerative diseases like multiple sclerosis (MS), according to preclinical results that show the inhibitors protect nerve cells from damage in mice and cell cultures. Researchers at Disarm Therapeutics presented the findings in a poster titled “…